Lichosik Marianna, Jung Anna, Jobs Katarzyna, Mierzejewska Anna, Zdanowski Robert, Kalicki Bolesław
Paediatric, Nephrology and Allergology Clinic, Military Institute of Medicine, Warsaw, Poland.
Department of Regenerative Medicine, Military Institute of Hygiene and Epidemiology, Warsaw, Poland.
Cent Eur J Immunol. 2015;40(4):447-53. doi: 10.5114/ceji.2015.56967. Epub 2016 Jan 15.
The aim of the study was to determine the usefulness of interleukin 18 (IL-18) and neutrophil-gelatinase associated lipocalin (NGAL) in the risk assessment of contrast nephropathy in children. The study included patients among whom radiological examinations were performed using intravascular contrast agent. The material consisted of 33 children (19 girls, 14 boys) aged 6.37 ±5.41 years. 20/33 (61%) of patients had hydronephrosis, 9/33 (27%) had other urinary tract defects referred as "no hydronephrosis" and 4/33 (12%) had urolithiasis. NGAL determination was performed with the use of Human Lipocalin-2 / NGAL Immunoassay. To determine the concentration of human IL-18 an ELISA Kit (MBL International Corporation) was used. There were no statistically significant differences in the concentrations of NGAL and IL-18 in serum determined before the procedure, and after the administration of contrast agent. Concentrations of NGAL and IL-18 were determined in urine three times: before the procedure, 2-4 hours after administration of the contrast agent, and 48 hours after the performed procedure. The analysis showed that the concentration of IL-18 and NGAL in urine did not differ significantly in three consecutive preformed measurements. The study has also found no statistically significant differences between serum creatinine before and 48 hours after injection of contrast. Implementation of new biomarkers such as NGAL and IL-18 expands the possibilities of renal function assessment in children undergoing radiological procedures using contrast agents. In examined children with normal or slightly impaired renal function they did not demonstrate the risk of contrast nephropathy.
本研究的目的是确定白细胞介素18(IL - 18)和中性粒细胞明胶酶相关脂质运载蛋白(NGAL)在儿童对比剂肾病风险评估中的作用。该研究纳入了使用血管内造影剂进行放射学检查的患者。研究材料包括33名儿童(19名女孩,14名男孩),年龄为6.37±5.41岁。20/33(61%)的患者患有肾积水,9/33(27%)有其他被称为“无肾积水”的尿路缺陷,4/33(12%)有尿路结石。使用人脂质运载蛋白-2/NGAL免疫测定法测定NGAL。使用ELISA试剂盒(MBL国际公司)测定人IL - 18的浓度。在检查前和注射造影剂后测定的血清中NGAL和IL - 18浓度无统计学显著差异。在尿液中三次测定NGAL和IL - 18的浓度:检查前、注射造影剂后2 - 4小时以及检查后48小时。分析表明,在连续三次测定中,尿液中IL - 18和NGAL的浓度无显著差异。该研究还发现,注射造影剂前和48小时后的血清肌酐之间无统计学显著差异。采用NGAL和IL - 18等新生物标志物扩大了对接受使用造影剂的放射学检查的儿童进行肾功能评估的可能性。在肾功能正常或轻度受损的受试儿童中,未显示出对比剂肾病的风险。